Generic Name and Formulations:
Clindamycin (as phosphate) 2%; vag crm.
Indications for CLINDESSE:
1 applicatorful intravaginally once.
History of enteritis or colitis.
Monitor for pseudomembranous colitis. Do not rely on contraceptive diaphragm or condom concurrently or for 5 days after treatment. Do not have vaginal intercourse or use tampons or douches during treatment. Pregnancy (Cat.B). Nursing mothers: not recommended.
May potentiate neuromuscular blockers.
Fungal vaginosis, vulvovaginal pruritus, headache.
Prefilled applicator (5g )—1
Endocrinology Advisor Articles
- Effect of HbA1c and Perioperative Glucose on Postoperative Mortality
- GLP-1 Agonists Superior to DPP-4 Inhibitors for Reducing HbA1c, Weight in T2D
- Semaglutide May Be Useful for Treating Obesity in People Without Diabetes
- Effect of Growth Hormone Treatment on BMD in Adults With Prader-Willi Syndrome
- Case for Continuous Glucose Monitoring in Youth-Onset Type 2 Diabetes
- American College of Physicians Releases 4 Guidelines for HbA1c Targets in T2D
- Dyslipidemia Drug Indications
- No Difference in Weight Loss Outcomes With Low-Fat vs Low-Carbohydrate Diet
- Damaging Effects of Gastric Bypass Surgery on Bone Mass and Microarchitecture
- Pioglitazone May Reduce Cardiovascular, Noncardiovascular Mortality in T2D
- HbA1c Levels Affect Serum Phospholipids, Inflammation inT2D, CVD
- No Cardiovascular Benefit With Fenofibrate in T2D and Hypertriglyceridemia
- Cardiovascular Function May Improve After Cure of Cushing Syndrome
- Primary Prevention Outcomes With Aspirin in T2D and Heart Failure
- Greater Bone Formation With Teriparatide vs Zoledronic Acid in Osteoporosis